Total Payments
$27,132
2024 Payments
$859.30
Companies
62
Transactions
470
Medicare Patients
2,217
Medicare Billing
$334,955
Payment Breakdown by Category
Research$17,437 (64.3%)
Food & Beverage$9,594 (35.4%)
Education$79.39 (0.3%)
Other$21.79 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17,437 | 8 | 64.3% |
| Food and Beverage | $9,594 | 455 | 35.4% |
| Education | $79.39 | 6 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21.79 | 1 | 0.1% |
Payments by Type
Research
$17,437
8 transactions
General
$9,695
462 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $9,207 | 51 | $0 (2022) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,700 | 2 | $0 (2022) |
| GRT US Holding, Inc. | $3,214 | 1 | $0 (2019) |
| Eli Lilly and Company | $1,215 | 1 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $819.80 | 29 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $654.30 | 30 | $0 (2024) |
| GENZYME CORPORATION | $488.40 | 24 | $0 (2022) |
| Lundbeck LLC | $438.54 | 19 | $0 (2024) |
| UCB, Inc. | $438.13 | 18 | $0 (2024) |
| ABBVIE INC. | $413.75 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $859.30 | 36 | Lundbeck LLC ($159.18) |
| 2023 | $1,125 | 50 | Lilly USA, LLC ($123.09) |
| 2022 | $3,266 | 64 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,975) |
| 2021 | $2,474 | 65 | Eli Lilly and Company ($1,215) |
| 2020 | $3,883 | 61 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($2,725) |
| 2019 | $4,693 | 68 | GRT US Holding, Inc. ($3,214) |
| 2018 | $9,640 | 57 | Sunovion Pharmaceuticals Inc. ($8,559) |
| 2017 | $1,190 | 69 | Sunovion Pharmaceuticals Inc. ($250.74) |
All Payment Transactions
470 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $9.79 | General |
| Category: Neurology | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: Neurology | ||||||
| 11/04/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.44 | General |
| Category: NEUROLOGY | ||||||
| 10/08/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: Neuroscience | ||||||
| 09/24/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Neurology | ||||||
| 09/10/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $28.64 | General |
| Category: NEUROLOGY | ||||||
| 09/10/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $23.39 | General |
| 08/20/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $31.92 | General |
| Category: NEUROLOGY | ||||||
| 08/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: PSYCHIATRY | ||||||
| 08/13/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: Rare Disease | ||||||
| 08/06/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $32.02 | General |
| Category: Neurology | ||||||
| 08/05/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $23.87 | General |
| Category: NEUROLOGY | ||||||
| 07/30/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: Neurology | ||||||
| 07/23/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $29.21 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $30.44 | General |
| Category: Neuroscience | ||||||
| 07/09/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $22.91 | General |
| Category: NEUROLOGY | ||||||
| 06/11/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/21/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: NEUROSCIENCE | ||||||
| 05/14/2024 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: NEUROLOGY | ||||||
| 05/13/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: Neurology | ||||||
| 05/07/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $28.58 | General |
| Category: NEUROLOGY | ||||||
| 05/07/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Rare Disease | ||||||
| 04/24/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $33.06 | General |
| Category: NEUROLOGY | ||||||
| 04/08/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures | Sunovion Pharmaceuticals Inc. | $5,619 | 2 |
| KF7013-04 | GRT US Holding, Inc. | $3,214 | 1 |
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,725 | 1 |
| An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia | Sunovion Pharmaceuticals Inc. | $2,689 | 2 |
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE (OPC-34712) IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,975 | 1 |
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $1,215 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 601 | 776 | $262,820 | $82,149 |
| 2022 | 12 | 548 | 765 | $246,285 | $81,666 |
| 2021 | 14 | 559 | 786 | $285,625 | $95,198 |
| 2020 | 13 | 509 | 703 | $258,695 | $75,943 |
Total Patients
2,217
Total Services
3,030
Medicare Billing
$334,955
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 152 | 241 | $60,250 | $22,410 | 37.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 33 | 34 | $27,200 | $9,858 | 36.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 110 | 150 | $30,000 | $9,174 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 57 | 57 | $25,650 | $8,819 | 34.4% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 15 | 15 | $34,950 | $7,188 | 20.6% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 13 | 13 | $32,565 | $6,632 | 20.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 41 | $12,300 | $5,261 | 42.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $9,800 | $3,721 | 38.0% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 14 | 14 | $7,000 | $2,201 | 31.4% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 18 | 18 | $4,500 | $1,579 | 35.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 18 | 19 | $4,750 | $1,486 | 31.3% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 18 | 20 | $3,150 | $983.90 | 31.2% |
| 92540 | Evaluation and testing for balance with recording | Office | 2023 | 11 | 11 | $2,200 | $958.10 | 43.6% |
| 92653 | Evaluation of brain response to sound for diagnosis of nervous system disorders with interpretation and report | Office | 2023 | 12 | 12 | $2,100 | $812.88 | 38.7% |
| 96139 | Administration of psychological or neuropsychological test by technician, each additional 30 minutes | Office | 2023 | 18 | 18 | $2,700 | $436.54 | 16.2% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 18 | 18 | $2,700 | $406.80 | 15.1% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 33 | 67 | $1,005 | $221.15 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 148 | 287 | $71,750 | $25,954 | 36.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 90 | 90 | $40,500 | $15,140 | 37.4% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 19 | 20 | $50,100 | $10,215 | 20.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 33 | 33 | $26,400 | $10,058 | 38.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 92 | 127 | $23,990 | $8,246 | 34.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 38 | 45 | $13,500 | $6,056 | 44.9% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2022 | 22 | 22 | $5,500 | $2,237 | 40.7% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 18 | 19 | $4,750 | $1,567 | 33.0% |
About Dr. David Lesch, M.D
Dr. David Lesch, M.D is a Neurology healthcare provider based in Suwanee, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942240932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Lesch, M.D has received a total of $27,132 in payments from pharmaceutical and medical device companies, with $859.30 received in 2024. These payments were reported across 470 transactions from 62 companies. The most common payment nature is "" ($17,437).
As a Medicare-enrolled provider, Lesch has provided services to 2,217 Medicare beneficiaries, totaling 3,030 services with total Medicare billing of $334,955. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Sleep Medicine
- Location Suwanee, GA
- Active Since 06/07/2006
- Last Updated 09/15/2009
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1942240932
Products in Payments
- Aptiom (Drug) $5,619
- REXULTI (Drug) $4,717
- Neridronic acid (Drug) $3,214
- SEP-363856 (Drug) $2,689
- APTIOM (Drug) $846.13
- AJOVY (Drug) $364.27
- RYTARY (Drug) $360.33
- GILENYA (Drug) $314.22
- Aimovig (Biological) $301.52
- VYEPTI (Biological) $296.13
- AUBAGIO (Drug) $294.20
- Briviact (Drug) $294.14
- Fycompa (Drug) $283.22
- KESIMPTA (Drug) $254.01
- AUSTEDO (Drug) $218.07
- EMGALITY (Drug) $188.11
- NUPLAZID (Drug) $181.45
- GOCOVRI (Drug) $180.52
- ZEPOSIA (Drug) $167.55
- Epidiolex (Drug) $165.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.